Switch theme
Sign up to access all valuation multiples
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
2006
126
LTM Revenue $287M
LTM EBITDA $100M
$2.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Protagonist Therapeutics has a last 12-month revenue (LTM) of $287M and a last 12-month EBITDA of $100M.
In the most recent fiscal year, Protagonist Therapeutics achieved revenue of $434M and an EBITDA of $256M.
Protagonist Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Protagonist Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $287M | XXX | $434M | XXX | XXX | XXX |
| Gross Profit | $287M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | $100M | XXX | $256M | XXX | XXX | XXX |
| EBITDA Margin | 35% | XXX | 59% | XXX | XXX | XXX |
| EBIT | $101M | XXX | $253M | XXX | XXX | XXX |
| EBIT Margin | 35% | XXX | 58% | XXX | XXX | XXX |
| Net Profit | $120M | XXX | $275M | XXX | XXX | XXX |
| Net Margin | 42% | XXX | 63% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Protagonist Therapeutics's stock price is $47.
Protagonist Therapeutics has current market cap of $2.9B, and EV of $2.4B.
See Protagonist Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.4B | $2.9B | XXX | XXX | XXX | XXX | $1.83 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Protagonist Therapeutics has market cap of $2.9B and EV of $2.4B.
Protagonist Therapeutics's trades at 5.5x EV/Revenue multiple, and 9.3x EV/EBITDA.
Equity research analysts estimate Protagonist Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Protagonist Therapeutics has a P/E ratio of 24.5x.
See valuation multiples for Protagonist Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.9B | XXX | $2.9B | XXX | XXX | XXX |
| EV (current) | $2.4B | XXX | $2.4B | XXX | XXX | XXX |
| EV/Revenue | 8.3x | XXX | 5.5x | XXX | XXX | XXX |
| EV/EBITDA | 23.8x | XXX | 9.3x | XXX | XXX | XXX |
| EV/EBIT | 23.4x | XXX | 9.4x | XXX | XXX | XXX |
| EV/Gross Profit | 8.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 24.5x | XXX | 10.7x | XXX | XXX | XXX |
| EV/FCF | 17.5x | XXX | 13.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialProtagonist Therapeutics's last 12 month revenue growth is -59%
Protagonist Therapeutics's revenue per employee in the last FY averaged $3.4M, while opex per employee averaged $1.4M for the same period.
Protagonist Therapeutics's rule of 40 is -210% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Protagonist Therapeutics's rule of X is -113% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Protagonist Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -59% | XXX | -37% | XXX | XXX | XXX |
| EBITDA Margin | 35% | XXX | 59% | XXX | XXX | XXX |
| EBITDA Growth | -142% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -210% | XXX | 0% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -113% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $3.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 32% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 42% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Protagonist Therapeutics acquired XXX companies to date.
Last acquisition by Protagonist Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Protagonist Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Protagonist Therapeutics founded? | Protagonist Therapeutics was founded in 2006. |
| Where is Protagonist Therapeutics headquartered? | Protagonist Therapeutics is headquartered in United States of America. |
| How many employees does Protagonist Therapeutics have? | As of today, Protagonist Therapeutics has 126 employees. |
| Who is the CEO of Protagonist Therapeutics? | Protagonist Therapeutics's CEO is Dr. Dinesh V. Patel, PhD. |
| Is Protagonist Therapeutics publicy listed? | Yes, Protagonist Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Protagonist Therapeutics? | Protagonist Therapeutics trades under PTGX ticker. |
| When did Protagonist Therapeutics go public? | Protagonist Therapeutics went public in 2016. |
| Who are competitors of Protagonist Therapeutics? | Similar companies to Protagonist Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Protagonist Therapeutics? | Protagonist Therapeutics's current market cap is $2.9B |
| What is the current revenue of Protagonist Therapeutics? | Protagonist Therapeutics's last 12 months revenue is $287M. |
| What is the current revenue growth of Protagonist Therapeutics? | Protagonist Therapeutics revenue growth (NTM/LTM) is -59%. |
| What is the current EV/Revenue multiple of Protagonist Therapeutics? | Current revenue multiple of Protagonist Therapeutics is 8.3x. |
| Is Protagonist Therapeutics profitable? | Yes, Protagonist Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Protagonist Therapeutics? | Protagonist Therapeutics's last 12 months EBITDA is $100M. |
| What is Protagonist Therapeutics's EBITDA margin? | Protagonist Therapeutics's last 12 months EBITDA margin is 35%. |
| What is the current EV/EBITDA multiple of Protagonist Therapeutics? | Current EBITDA multiple of Protagonist Therapeutics is 23.8x. |
| What is the current FCF of Protagonist Therapeutics? | Protagonist Therapeutics's last 12 months FCF is $136M. |
| What is Protagonist Therapeutics's FCF margin? | Protagonist Therapeutics's last 12 months FCF margin is 47%. |
| What is the current EV/FCF multiple of Protagonist Therapeutics? | Current FCF multiple of Protagonist Therapeutics is 17.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
